We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
-0.31%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$6.88B
AUM Growth
-$822M
Cap. Flow
-$1.07B
Cap. Flow %
-15.57%
Top 10 Hldgs %
44.23%
Holding
173
New
23
Increased
20
Reduced
28
Closed
33

Top Buys

Rank Stock Value
1
ICVX
Icosavax, Inc. Common Stock
ICVX
+$65.2M
2
PRCT icon
Procept Biorobotics
PRCT
+$63.6M
3
FOLD
Amicus Therapeutics
FOLD
+$35.2M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$32.5M
5
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$31.4M

Top Sells

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$93.6M
2
NVRO
NEVRO CORP.
NVRO
+$73.1M
3
KDMN
Kadmon Holdings, Inc.
KDMN
+$60.8M
4
MDT icon
Medtronic
MDT
+$55.9M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$31.1M

Sector Composition

Rank Sector Weight
1 Healthcare 83.92%
2 Financials 0.85%
3 Industrials 0.17%
4 Consumer Discretionary 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TDOC icon
151
CALL
Teladoc Health
TDOC
$1.66B
– –
-100,000
Closed -$16.6M
TKNO icon
152
Alpha Teknova
TKNO
$266M
– –
-30,000
Closed -$712K
TNGX icon
153
Tango Therapeutics
TNGX
$4.21B
– –
-500,000
Closed -$5.69M
NARI
154
DELISTED
Inari Medical, Inc. Common Stock
NARI
– –
-310,437
Closed -$29M
SILK
155
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
– –
-147,133
Closed -$7.04M
GRTX
156
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
– –
-254,664
Closed -$2.5M
TCRR
157
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
– –
-30,753
Closed -$505K
SGTX
158
DELISTED
Sigilon Therapeutics, Inc. Common Stock
SGTX
– –
-9,615
Closed -$1.34M
PLXP
159
DELISTED
PLx Pharma Inc. Common Stock
PLXP
– –
-57,459
Closed -$793K
LGV.U
160
DELISTED
Longview Acquisition Corp. II Units, each consisting of one share of Class A Common Stock and one-fifth of one redeemable Warrant
LGV.U
– –
-500,000
Closed -$5.04M
SRRA
161
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
– –
-66,655
Closed -$1.3M
DRNA
162
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
– –
-800,000
Closed -$29.9M
XLRN
163
DELISTED
Acceleron Pharma
XLRN
– –
-226,760
Closed -$28.5M
KDMN
164
DELISTED
Kadmon Holdings, Inc.
KDMN
– –
-15,711,334
Closed -$60.8M
CMIIU
165
DELISTED
CM Life Sciences II Inc. Unit
CMIIU
– –
-1,250,000
Closed -$16.8M
CEREW
166
DELISTED
Cerevel Therapeutics Holdings, Inc. Warrant
CEREW
– –
-133,066
Closed -$1.91M
CHFW.U
167
DELISTED
Consonance-HFW Acquisition Corp. Units, each consisting of one Class A Ordinary Share, and one-third
CHFW.U
– –
-500,000
Closed -$5.2M
SCPE.WS
168
DELISTED
SC Health Corporation Warrants, each whole warrant exercisable for one Class A ordinary share at an
SCPE.WS
– –
-500,000
Closed -$1.05M
3 4 5 6
7

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q3 2021 Portfolio in Review

As of Q3 2021, Perceptive Advisors held 173 positions worth $6.88B, down 11% from $7.71B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Perceptive Advisors withdrew a net $1.07B in Q3 2021, closing 33 positions and reducing 28 holdings. Its most notable exit was Kadmon Holdings, Inc., an estimated $60.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 85% a quarter earlier, followed by Financials and Industrials.

Against the trend, Perceptive Advisors opened a new position in Icosavax, Inc. Common Stock worth $56.9M.

  • Perceptive Advisors's largest Q3 2021 buy was Icosavax, Inc. Common Stock: 1,922,549 shares worth $56.9M.
  • Perceptive Advisors added most to Amicus Therapeutics in Q3 2021, an estimated $35.2M increase.
  • Perceptive Advisors's biggest Q3 2021 reduction was United Therapeutics, cutting an estimated $93.6M.
  • Perceptive Advisors fully exited Kadmon Holdings, Inc. in Q3 2021, selling an estimated $60.8M.
  • Perceptive Advisors's ten largest holdings make up 44% of its $6.88B portfolio in Q3 2021.
  • Perceptive Advisors opened 23 new positions and closed 33 in Q3 2021.
  • Perceptive Advisors's portfolio value fell 11% quarter-over-quarter to $6.88B.

Based on Perceptive Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.